FDA Re-Approves Tysabri, Recommends Second-Line Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.
You may also be interested in...
Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed
Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.
Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.
Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.